Additionally, magnetic resonance imaging (MRI) conducted on a subset of participants from the SURPASS-3 trial showed that, after 52 weeks of treatment with tirzepatide, liver fat content was reduced by 30% or more in 67% to 79% of participants, and VAT volume decreased by 16% to 25% [62]
Although the absolute risk remains relatively low, studies show a modest but consistent increase in gallstones and cholecystitis among treated patients compared to placebo
Torreele, E., Van Der Sluiszen, A
The significance of microsurgical varicocelectomy in the treatment of subclinical varicocele
Starting a GLP-1 medication with endometriosis The standard approach applies: start low, titrate slowly
NooCube also includes Cat's Claw Extract which may support brain health but its effects aren't well documented [27]